By Measuring The Ability To Specifically Bind A Target Molecule (e.g., Antibody-antigen Binding, Receptor-ligand Binding, Etc.) Patents (Class 506/9)
  • Patent number: 11131674
    Abstract: Microarray compositions suitable for analysis by one or several spectrographic methods are disclosed. In an embodiment, a microarray composition includes a three-dimensional solid support and a plurality of reactive microbeads positioned on the solid support in spatially distinct and addressable locations.
    Type: Grant
    Filed: September 7, 2019
    Date of Patent: September 28, 2021
    Assignee: ADEPTRIX CORP.
    Inventor: Vladislav B. Bergo
  • Patent number: 11131676
    Abstract: The present invention provides a method of using increased levels of one or more biomarkers to identify subjects having non-celiac gluten sensitivity or non-celiac wheat sensitivity. The identification would aid the physician or health professional to determine a specific treatment for the patient, for example, a diet that eliminates wheat, rye, and/or barley. In one embodiment, the biomarkers are one or more of soluble CD 14 (sCD14), lipopolysaccharide-binding protein (LBP), anti-lipopolysaccharide antibodies, anti-flagellin antibodies, anti-gliadin antibodies, and intestinal fatty acid-binding protein (FABP2). The present invention also provides a method of using the same markers to monitor the response to treatment for non-celiac wheat sensitivity in a subject.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: September 28, 2021
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventor: Armin Alaedini
  • Patent number: 11125743
    Abstract: Provided herein are methods and systems for low-cost, low-equipment detection of pathogens in biological sample. In particular, provided herein is a low-cost method for detecting norovirus that provides reliable, visible test with femtomolar, attomolar, and zeptomolar detection limits and that uses materials suitable for deployment of the methods in the field.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: September 21, 2021
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Alexander Green, Duo Ma, Luhui Shen, Chris Diehnelt
  • Patent number: 11124832
    Abstract: A serum microRNA (miRNA) marker suitable for early screening and diagnosis of ossification of posterior longitudinal ligament (OPLL) and its application in the diagnostic reagent or kit for the OPLL. Biomarker miRNA-563, miRNA-196b, miRNA-10a and miRNA-129 have high diagnostic value for OPLL, and the development and application of the related serum miRNA biomarker detection reagent kit. It can be applied in the screening of ossification of posterior longitudinal ligament disease, supporting the diagnosis of OPLL more quickly and accurately, evaluate the patient's ossification condition, and may lay down the foundation for improving clinical therapeutic effect.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: September 21, 2021
    Assignee: THE SECOND MILITARY MEDICAL UNIVERSITY
    Inventors: Yang Liu, Chen Xu, Hao Zhang, Wen Yuan, Peng Cao, Huiqiao Wu, Yuanyuan Chen, Xiaolong Shen
  • Patent number: 11125740
    Abstract: Disclosed is a method for measuring an immunostimulatory response of an immune cell, including (i) bringing a measurement target immune cell into contact with an immunostimulator, (ii) forming a contact surface with a substance different from the measurement target immune cell on the measurement target immune cell, (iii) bringing the measurement target immune cell into contact with a capturing body that binds to a surface antigen on the contact surface and is capable of generating an optical signal, (iv) detecting the optical signal generated from the capturing body, and (v) determining whether or not the measurement target immune cell from which the contact surface has been eliminated before detecting the optical signal has an immunostimulatory response, based on the detected optical signal.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: September 21, 2021
    Assignee: SYSMEX CORPORATION
    Inventors: Masatoshi Yanagida, Keiko Miwa, Yuma Oka
  • Patent number: 11117132
    Abstract: A biocompatible micropillar array substrate (MAS) and methods for preparing the biocompatible MAS are provided. In on example, the biocompatible MAS includes multiple micropillars made from a biocompatible polymer. The biocompatible MAS may be prepared using a replica fabricated based on a silicon MAS. The configuration of the multiple micropillars of the silicon MAS and a configuration of the multiple micropillars of the biocompatible MAS are the same.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: September 14, 2021
    Inventor: Lian Liu
  • Patent number: 11116785
    Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.
    Type: Grant
    Filed: December 30, 2019
    Date of Patent: September 14, 2021
    Assignee: Rosalind Franklin University of Medicine and Science
    Inventor: Michelle L. Hastings
  • Patent number: 11111280
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: September 7, 2021
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Andrea Mahr, Toni Weinschenk, Valentina Goldfinger, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 11111603
    Abstract: This invention relates to methods and materials for multiplexed utilization of collections of functional ligands, particularly to methods and materials for selecting for and/or utilizing particular desirable traits of functional ligands in a multiplexed manner, and more particularly to methods and materials for selecting for and/or utilizing particular structural changes of functional ligands in a multiplexed manner.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: September 7, 2021
    Assignee: Base Pair Biotechnologies, Inc.
    Inventors: George W. Jackson, Robert Batchelor, Alexander S. Chiu, Rafal Drabek, Deepak Thirunavukarasu, Caitlin Bruns
  • Patent number: 11111469
    Abstract: A device for cell culture comprising: a main body (11); said main body (11) comprises a plurality of circular portions (21-23); said device comprises a plurality of caps (51-53); each of said plurality of caps (51-53) comprises a base structure (58) having a circular hole (57), housing an upper slide (54) and an elastomeric layer (56) secured to said slide (54); said elastomeric layer (56) has a rectangular hole (59); said plurality of caps (51-53) being adapted to cooperate with said plurality of circular portions (21-23); each of said plurality of circular portions (21-23) each comprise an inlet hole (64-66) and an outlet hole (67-69) aligned with the long side of said rectangular hole (59), to perfuse the culture chamber (12-14) located in said rectangular hole (59) of said elastomeric layer (56).
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: September 7, 2021
    Assignee: POLITECNICO DI MILANO
    Inventors: Manuela Teresa Raimondi, Matteo Lagana
  • Patent number: 11111528
    Abstract: The present invention provides an apparatus and a method for detecting the presence of and/or determining the amount of a label-free microRNA using an atomic force microscope. The method is extremely selective and/or ultrasensitive. In particular, the present invention provides a cantilever comprising a probe that selectively binds to a double strand of DNA/RNA hybrid complex. The probe comprises a hybrid binding domain (HBD) or a variant thereof.
    Type: Grant
    Filed: January 22, 2017
    Date of Patent: September 7, 2021
    Assignees: POSCO, POSTECH ACADEMY-INDUSTRY FOUNDATION
    Inventors: Joon Won Park, Joung Hun Kim, Young Kyu Kim, Hyun Seo Koo, Yoon Hee Lee
  • Patent number: 11111489
    Abstract: Described herein is a method for determining a lymphocyte cell receptor chain sequence specific to a unique antigen, comprising: sorting a plurality of antigens into a plurality of reaction mixtures, wherein the sorting comprises adding a unique antigen of the plurality of antigens to a unique subset of the plurality of reaction mixtures such that two different unique antigens are not added to the unique subset; contacting each reaction with a biological sample comprising a plurality of lymphocytes; separating a target lymphocyte from a subset of the plurality of lymphocytes, wherein the target lymphocyte recognizes the unique antigen; after separating the target lymphocyte, sequencing nucleic acids of the target lymphocyte to obtain the lymphocyte receptor chain sequence, wherein the sequencing is performed by single-cell sequencing; and detecting the unique antigen, wherein the detecting comprises: computing a frequency of lymphocyte cells that express the lymphocyte receptor chain sequence.
    Type: Grant
    Filed: January 6, 2021
    Date of Patent: September 7, 2021
    Assignee: Think Therapeutics, Inc.
    Inventors: David Gifford, Brandon Carter
  • Patent number: 11111281
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: September 7, 2021
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Colette Song, Heiko Schuster, Daniel Johannes Kowalewski, Oliver Schoor, Jens Fritsche, Toni Weinschenk, Harpreet Singh
  • Patent number: 11104951
    Abstract: By a genome-wide gene analysis of expression profiles of known or putative gene sequences in peripheral blood and biopsy samples, the present inventors have identified a consensus set of gene expression-based molecular biomarkers for distinguishing liver transplantation patients who have Acute Rejection (AR), Hepatitis C Virus Recurrence (HCV-R), both AR/HCV-R, or Acute Dysfunction No Rejection (ADNR). These molecular biomarkers are useful for diagnosis, prognosis and monitoring of liver transplantation patients.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: August 31, 2021
    Assignees: The Scripps Research Institute, Northwestern University
    Inventors: Daniel Salomon, Josh Levitsky, Sunil Kurian, Michael Abecassis
  • Patent number: 11104959
    Abstract: The present invention refers to an in vitro method for screening for subjects at risk of developing pancreatic cancer or intraductal papillary mucinous neoplasm of the pancreas (IPMN) comprising: (a) measuring the expression pattern or level of at least hsa-miR-33a*, or of at least hsa-miR-320a, or of at least hsa-let-7e, or of at least hsa-let-7f, or of at least hsa-miR-1257, or of at least hsa-miR-1304, or of at least hsa-miR-151b, or of at least hsa-miR-3120-3p, or of at least hsa-miR-3133, or of at least hsa-miR-3714, or of at least hsa-miR-4468, or of at least hsa-miR-4639-5p, or of at least hsa-miR-4713-5p, or of at least hsa-miR-4714-5p, or of at least hsa-miR-4770, or of at least hsa-miR-548d-3p, or of at least hsa-miR-761, obtained from an isolated biological sample of the subjects to be screened; and (b) comparing said expression pattern or level of at least hsa-miR-33a*, or of at least hsa-miR-320a, or of at least hsa-let-7e, or of at least hsa-let-7f, or of at least hsa-miR-1257, or of at least hs
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: August 31, 2021
    Assignees: Advanced Marker Discovery, S.L., Centro de Investigación Biomedica en Red, Hospital Clinic de Barcelona
    Inventors: Meritxel Gironella Cos, Antoni Castells Garangou
  • Patent number: 11104942
    Abstract: A method for identification of the most abundant oligonucleotide species in a library of oligonucleotides comprising more than 106 oligonucleotide species, wherein the oligonucleotides of the library of oligonucleotides are not inherently capable of exponential amplification by PCR and include a coding sequence, which is characteristic of one oligonucleotide specie of the library of oligonucleotides and only one fixed sequence, which is present in a plurality of oligonucleotide species of the library of oligonucleotides, said fixed sequence being located on a 5? side of the coding sequence, and wherein the method comprises specifically amplifying the sequence of a hybridised oligonucleotide species using the steps of: incubating the library of oligonucleotides under conditions of hybridization such as to allow complementary coding sequences to hybridize and form hybridized oligonucleotide species; extending a 3? end of one or more of the hybridised oligonucleotide species, having only one fixed sequence, to p
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: August 31, 2021
    Assignee: Guangdong Maijinjia Biotechnologies, Co. Ltd.
    Inventor: Thorleif Moeller
  • Patent number: 11104946
    Abstract: This invention provides triple primer and probe combinations that function efficiently in PCR-based amplification systems using undigested genomic DNA and are useful for the diagnosis and subsequent treatment of systemic inflammatory disease.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: August 31, 2021
    Assignee: Inflammatix, Inc.
    Inventors: Wensheng Nie, Timothy Sweeney
  • Patent number: 11098094
    Abstract: The present invention relates to proteins consisting of an artificial DNA-binding domain (DBD) and related molecules and uses thereof. In particular, the proteins are ZF-DBD or TALE-DBD and are used for the treatment of eye disorders caused by gain of function mutation. The disorder may be ADRP, in particular ADRP caused by mutation in the rhodopsin gene. The present invention also relates to a method to identify cis-regulatory elements and to modulate them via DBDs.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: August 24, 2021
    Assignee: FONDAZIONE TELETHON
    Inventors: Salvatore Botta, Enrico Maria Surace, Elena Marrocco
  • Patent number: 11096998
    Abstract: BCMA-specific fibronectin type III (FN3) domains, BCMA-targeting chimeric antigen receptors (CARs) comprising the FN3 domains, and engineered BCMA-targeting immune cells expressing the CARs are described. Also described are nucleic acids and expression vectors encoding the FN3 domains and the CARs, recombinant cells containing the vectors, and compositions comprising the engineered immune cells. Methods of making the FN3 domains, CARs, and engineered immune cells, and methods of using the engineered immune cells to treat diseases including cancer are also described.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: August 24, 2021
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Chen Ni Chin, John Lee, Timothy McCabe, Jill Mooney, Michael Naso, William Strohl
  • Patent number: 11085071
    Abstract: The present invention discloses a method of detecting the presence of mutated genes, mRNAs or microRNAs in a subject. The method comprises the following steps: (1) Provide a body fluid sample containing cells, circulating tumor cells (CTCs), and/or extracellular vesicles (EVs); and use an analyzer having overhang molecular beacons to measure fluorescence signals generated by interactions between the body fluid sample and the overhang molecular beacons, so as to detect the presence of the mutated genes, mRNAs or microRNA. Furthermore, a biochip comprising a gold coating substrate and tethered lipoplex nanoparticles encapsulating the overhang molecular beacons is also provided in the invention.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: August 10, 2021
    Assignee: SPOT BIOSYSTEMS LTD.
    Inventors: Ly James Lee, Jiaming Hu, Kwang Joo Kwak
  • Patent number: 11083784
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: August 10, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Anita Wiebe, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 11085912
    Abstract: Methods are described for identifying CDI patients as well as CDI patients at risk for recurrence. Embodiments include: (1) flow cytometry of circulating peripheral blood mononuclear cells (PBMC) to phenotype for the less efficient immunoglobulin response to bacterial toxins and surface antigens that characterizes patients who will become recurrent; (2) stratification by means of complete blood count (CBC) using a Coulter counter to detect the differences in lower angle light scatter (LAL), which has a larger range in the recurrent population; and (3) stratification by means of complete blood count (CBC) using a Coulter counter to detect the lower axial light loss (AL2) exhibited in recurrent patients.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: August 10, 2021
    Assignee: University of Cincinnati
    Inventors: Mary Elizabeth Yacyshyn, Bruce R. Yacyshyn, Julianne Qualtieri
  • Patent number: 11077093
    Abstract: The present invention relates to a drug that is for treating or preventing cancer, that is effective in the treatment of cancer, and that comprises a combination of an ALK inhibitor and a VEGF inhibitor. The present invention also relates to a method for treating or preventing cancer and a method for inhibiting tumor growth.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: August 3, 2021
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hiroshi Sakamoto, Toshiyuki Tsukaguchi
  • Patent number: 11078532
    Abstract: This disclosure provides methods for determining relative abundance of one or more non-host species in a sample from a host. Also provided are methods involving addition of known concentrations of synthetic nucleic acids to a sample and performing sequencing assays to identify non-host species such as pathogens. Also provided are methods of tracking samples, tracking reagents, and tracking diversity loss in sequencing assays.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: August 3, 2021
    Assignee: Karius, Inc.
    Inventors: Fred C. Christians, Igor D. Vilfan, Michael Kertesz, Timothy A. Blauwkamp, Shivkumar Venkatasubrahmanyam, Michael Rosen, Rene Sit
  • Patent number: 11079394
    Abstract: Methods for detecting angiopoietin-2 (Angpt-2) and/or thrombospondin-2 (Tsp-2) in a sample involve obtaining or having obtained a blood or plasma sample from a subject; and detecting Angpt-2 and Tsp-2 in the sample. Detecting can involve performing an assay to determine whether the sample includes Angpt-2 and/or Tsp-2 or elevated levels of Angpt-2 and/or Tsp-2. Elevated levels are indicative of acute heart failure.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: August 3, 2021
    Assignees: Vanderbilt University, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Thomas J. Wang, Deepak K. Gupta, Quinn S. Wells, Robert E. Gerszten
  • Patent number: 11073310
    Abstract: Thermal control devices adapted to provide improved control and efficiency in temperature cycling are provided herein. Such thermal control device can include a thermoelectric cooler controlled in coordination with another thermal manipulation device to control an opposing face of the thermoelectric cooler and/or a microenvironment. Some such thermal control devices include a first and second thermoelectric cooler separated by a thermal capacitor. The thermal control devices can be configured in a planar configuration with a means for thermally coupling with a planar reaction vessel of a sample analyzer for use in thermal cycling in a polymerase chain reaction of the fluid sample in the reaction vessel. Methods of thermal cycling using such a thermal control devices are also provided.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: July 27, 2021
    Assignee: Cepheid
    Inventors: David Fromm, Tien Phan, Matthew Piccini
  • Patent number: 11066697
    Abstract: Methods, devices, and kits for performing rapid, highly sensitive, high throughput, accurate, and flexible detection and quantification of nucleic acids based on highly optimized rolling circle amplification are provided. The methods, devices, and kits can be used to detect and track an emergent virus or other pathogen, including SARS-CoV-2, to test and diagnose individual patients with respect to a specific pathogen or disease, including COVID-19, and to detect and analyze cellular nucleic acids. The methods and devices also can be used to detect fragments and variants of DNA or RNA, including those present in cancer cells. The methods, devices, and kits are suitable for use in both high throughput screening carried out in centralized testing laboratories and in point-of-care testing devices used in the field, at home, in the workplace, or at public facilities for rapid detection and diagnosis.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: July 20, 2021
    Assignee: Northeastern University
    Inventors: Tania Konry, Ji Won Lim
  • Patent number: 11066704
    Abstract: The present invention relates to technologies for preparing a tagging oligonucleotide. By analyzing exquisitely a non-complementarity level of a first tagging part, the first aspect of the present invention permits to more efficiently and easily select a suitable tagging sequence among a multitude of sequences generated theoretically. In addition, according to the second aspect of the present invention, when a nucleotide sequence for a tagging portion is first selected, one or more regions in a target nucleic acid sequence having a non-complementarity level to the nucleotide sequence for the tagging portion are found, and then a nucleotide sequence for a targeting portion is determined, tagging oligonucleotides for detecting various target nucleic acid sequences can prepared by using the fewest number of nucleotide sequences for the tagging portion and a third template.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: July 20, 2021
    Assignee: SEEGENE, INC.
    Inventors: Jong Yoon Chun, Gi-Seok Yoon
  • Patent number: 11066710
    Abstract: The present invention relates to the methods and products for detection of colorectal cancer. Additionally, the present invention relates to methods and products for determining the probability, risk or incidence of colorectal cancer and of colorectal cancer metastasis. The products and methods of the present invention include detecting the level of expression of COL10A1 or MMP11, in combination, from samples, including tissue samples, from humans who currently have been diagnosed with cancer or who were previously diagnosed with cancer and those who are thought to have cancer and are undergoing diagnosis.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: July 20, 2021
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Michael Stürzl, Roland S. Croner, Andreas Konrad
  • Patent number: 11060084
    Abstract: The present invention is directed to SH3 domain derivatives having a specific binding affinity to a target molecule. In this respect, the invention provides SH3 domain derivatives of nephrocystin (NPHP1) and the Tec kinase. The invention also provides a method for the production of a library comprising recombinant derivatives of NPHP1 or the Tec kinase SH3 domains and a method for selecting from the library one or more derivatives of the SH3 domain of nephrocystin (NPHP1) or the Tec kinase having a specific binding affinity to a target molecule.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: July 13, 2021
    Assignee: Next Biomed Therapies Oy
    Inventor: Kalle Saksela
  • Patent number: 11059855
    Abstract: The present invention provides a new methodology combining MD simulations and database-guided high-throughput screening to rationally design pore forming membrane-active peptides. The present inventive methodology is able to allow tuning of a range of structural and functional properties such as pore size and selectively targeting membranes with specific lipid compositions. The present inventive methods will ultimately allow de novo design of membrane-active peptides for a wide range of biomedical applications, including for example, antimicrobial agents.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: July 13, 2021
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Charles H. Chen, Martin B. Ulmschneider
  • Patent number: 11060132
    Abstract: The present disclosure describes various improved methods for imaging at least one target in a sample, including methods employing an adapter strand oligonucleotide and a bridge strand oligonucleotide. Some methods also employ bouncer oligonucleotides and/or blocker oligonucleotides. Some methods also use two partial docking strands to detect proximity of the partial docking strands to each other.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: July 13, 2021
    Assignee: Ultivue, Inc.
    Inventors: Xi Chen, Stephanie Hennek
  • Patent number: 11052407
    Abstract: A dielectrophoresis-based in-droplet cell concentrator is disclosed herein. The concentrator can include a concentration microchannel having an input port and two or more outlet ports. The input port introduces cell-encapsulated droplets or particle-encapsulated droplets into the microchannel; a first outlet port receives droplets including most of the cells or particles and a second output port receives droplets including few cells or particles. The concentrator also can include a pair of electrodes. When voltage is applied, the electrodes will create an electric field across the microchannel. The concentrator adds new capabilities to droplet microfluidics operations, such as adjusting concentrations of cells in droplets, separating cells of different properties from inside droplets, and solution exchange.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: July 6, 2021
    Assignee: THE TEXAS A&M UNIVERSITY SYSTEM
    Inventors: Arum Han, Song-I Han
  • Patent number: 11054413
    Abstract: The present invention provides a device for assaying living cells comprising a substrate, wherein the substrate comprises one or more tethering molecules which adhere to the substrate and are capable of interacting with cell membranes of the cells, wherein the cells maintain a free-floating, non-adherent character when bound to the one or more tethering molecules.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: July 6, 2021
    Assignees: UNIVERSITY OF MARYLAND, COLLEGE PARK, UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Stuart Martin, Christopher M. Jewell, James I. Andorko, Elisabeth Lily Sooklal, Rebecca Whipple Bettes, Kristi Chakrabarti
  • Patent number: 11053281
    Abstract: Disclosed herein are peptoids and related compounds, including peptoid affinity ligands for binding and/or purifying immunoglobulins, immunoglobulin fragments or immunoglobulin fusion proteins thereof. Methods of making peptoid affinity ligands and using the same to bind, purify and/or isolate immunoglobulins and related compounds are also disclosed. Such peptoid affinity ligands comprise a peptoid compound consisting of sequentially coupled peptoid residues forming a peptoid backbone, with one or more functional groups appended to a nitrogen of the peptoid residues of the peptoid backbone configured to provide the desired binding affinity.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: July 6, 2021
    Assignee: MIKE-ANN, LLC
    Inventors: Andrew J. Murphy, Tee Bordelon, Michael Crapanzano
  • Patent number: 11053282
    Abstract: Disclosed herein are peptoids and related compounds, including peptoid affinity ligands, and hybrid peptoids, for binding and/or purifying immunoglobulins, immunoglobulin fragments or immunoglobulin fusion proteins thereof. Methods of making peptoid affinity ligands and using the same to bind, purify and/or isolate immunoglobulins and related compounds are also disclosed. Such peptoid affinity ligands comprise a peptoid compound consisting of sequentially coupled peptoid residues forming a peptoid backbone, with one or more functional groups appended to a Nitrogen of the peptoid residues of the peptoid backbone configured to provide the desired binding affinity. The peptoids can further comprise a peptoid backbone with at least one functional group coupled to an alpha carbon (C) of a peptide bond in the peptoid backbone thereby forming a hybrid peptoid.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: July 6, 2021
    Assignee: MIKE-ANN, LLC
    Inventors: Andrew J. Murphy, Tee Bordelon, Michael Crapanzano
  • Patent number: 11046951
    Abstract: Methods for display of recombinant whole immunoglobulins or immunoglobulin libraries on the surface of eukaryote host cells, including yeast and filamentous fungi, are described. The methods are useful for screening libraries of recombinant immunoglobulins in eukaryote host cells to identify immunoglobulins that are specific for an antigen of interest.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: June 29, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Bianka Prinz, Natarajan Sethuraman, Dongxing Zha, Stefan Wildt, Piotr Bobrowicz
  • Patent number: 11046932
    Abstract: The present invention relates to a method for producing renal cells, comprising overexpressing Hnf1b and Pax8, and optionally Hnf4a and/or Emx2 in differentiated cells.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: June 29, 2021
    Assignee: Albert-Ludwigs-Universitaet Freiburg
    Inventors: Soeren Lienkamp, Michael Kaminski, Sebastian Arnold, Gerd Walz
  • Patent number: 11035854
    Abstract: The present invention relates to methods and systems for testing for the presence of a material such as one or more analyte types within a sample and more particularly, for improved single enzyme-linked immunosorbent assay (sELISA) testing as well as other variants of single-enzyme linked molecular analysis (SELMA). Background and false positives are reduced due to the presence of at least two detection cycles where each detection cycle comprises the steps of a) triggering a signal from captured and labelled analyte(s), b) recording of the number and positions of capture sites exhibiting a signal from the captured and labelled analyte(s), c) and before a further detection cycle is performed, deactivation of signal(s).
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: June 15, 2021
    Assignee: Selma Diagnostics APS
    Inventor: Andreas Hjarne Kunding
  • Patent number: 11035849
    Abstract: The present technology provides a method of determining whether a subject with cancer is likely to experience one or more metastases. The method may include determining a methylation level of at least one gene selected from the group consisting of BEND4, CDH4, C1QL3, ERG, GP5, GSC, HTR1B, LMX1B, MCF2L2, PENK, REC8, RUNX3, PAX5, PCDHIO, SP8, SP9, STAC2, ULBP1, UNC13A, VIM, VWC2 in a subject-derived sample and then comparing the subject-derived methylation level determined in step a) with a normal control level obtained from a normal sample. Thereafter, the method may include correlating an increase of said subject-derived methylation level as compared to the normal control level to a diagnosis the subject as likely to experience one or more metastases.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: June 15, 2021
    Assignee: The Translational Genomics Research Institute
    Inventor: Bodour Salhia
  • Patent number: 11033407
    Abstract: The present invention provides a three-dimensional bioprinter for fabricating cellular constructs such as tissues and organs using electromagnetic radiation (EMR) at or above 405 nm. The bioprinter includes a material deposition device comprising a cartridge for receiving and holding a composition which contains biomaterial that cures after exposure to EMR. The bioprinter also includes an EMR module that emits EMR at a wavelength of about 405 nm or higher. Also provided is a bioprinter cartridge which contains cells and a material curable at a wavelength of about 405 nm or greater. The cells are present in a chamber and are extruded through an orifice to form the cellular construct.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: June 15, 2021
    Assignee: ALLEVI, INC.
    Inventors: Ricardo D. Solorzano, Sohaib K. Hashmi, Daniel Cabrera
  • Patent number: 11034997
    Abstract: The present invention describes methods for performing higher multiplexed real-time PCR for detection and quantitation of target nucleic acids using tagged hydrolysis probes.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: June 15, 2021
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Igor Kozlov, Amar Gupta, Randall Saiki, Alison Tsan
  • Patent number: 11021735
    Abstract: Methods of detecting and amplifying short RNAs are provided.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: June 1, 2021
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Man Cheng, Xiao-Song Gong, Yan Wang, Adam M. McCoy
  • Patent number: 11017896
    Abstract: Embodiments facilitate predicting a patient prostate cancer (PCa) DECIPHER risk group. A first set of embodiments relates to training of a machine learning classifier to compute a probability that a patient is a member of a DECIPHER low/intermediate risk group based on radiomic features extracted from bi-parametric magnetic resonance imaging (bpMRI) images. A second set of embodiments relates to classifying a patient as a member of DECIPHER low/intermediate risk group, or DECIPHER high-risk group, based on radiomic features extracted from bpMRI imagery of the patient.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: May 25, 2021
    Assignees: Case Western Reserve University, The Cleveland Clinic Foundation
    Inventors: Anant Madabhushi, Lin Li, Andrei S. Purysko, Rakesh Shiradkar
  • Patent number: 11016086
    Abstract: The invention generally relates to methods and devices for transferring a sample into a cartridge for processing. Methods of the invention include providing a vessel containing a sample, coupling the sample to a cartridge configured to process the sample at an interface, in which the interface is configured to provide communication between the vessel and the cartridge, introducing a fluid, capture particles, or both from the cartridge into the vessel, and transferring the sample, fluid, and capture particles from the vessel and into the cartridge for processing.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: May 25, 2021
    Assignee: DNAE Group Holdings Limited
    Inventor: James H. Macemon
  • Patent number: 11011265
    Abstract: Embodiments facilitate stratification of a patient according to prostate cancer (PCa) risk. A first set of embodiments relates to training of a machine learning classifier to compute a probability that a patient has a low-risk of PCa progression based on intratumoral radiomic features and peritumoral radiomic features extracted from multi-parametric magnetic resonance imaging (mpMRI) images. A second set of embodiments relates to classifying a patient as low-risk of PCa progression, or high-risk of PCa progression, based on radiomic features extracted from mpMRI imagery of the patient.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: May 18, 2021
    Assignee: Case Western Reserve University
    Inventors: Anant Madabhushi, Ahmad Algohary, Rakesh Shiradkar
  • Patent number: 11008629
    Abstract: Kits and methods are provided for performing multiplex LAMP reactions. These kits and methods are directed to specific and sensitive methods of target nucleic acid detection and more specifically pathogen diagnostics such as detection of Coronavirus. The kits and methods utilize a plurality of sets of oligonucleotide primers for targeting the viral nucleic acid target.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: May 18, 2021
    Assignee: New England Biolabs, Inc.
    Inventors: Nathan Tanner, Yinhua Zhang, Gregory Patton, Guoping Ren, Zhiru Li, Nicole Nichols
  • Patent number: 10995359
    Abstract: The present invention addresses the problem of providing a novel method for classifying cancer cells by an analysis method in which measurement of the activity of two types of protein kinase is used. Cancer cells are newly classified and drug sensitivity is predicted on the basis of the ratio of the activity of two types of protein kinase derived from the same sample.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: May 4, 2021
    Assignee: NITTO BOSEKI CO., LTD.
    Inventors: Masayuki Wakabayashi, Natsuki Sato, Hideki Ishihara
  • Patent number: 10993418
    Abstract: Kits and methods providing measurement of tumor burden in a patient derived xenograft (PDX) mouse are described. Exemplary embodiments contemplate taking a sample, typically a blood sample, from a PDX mouse and using a real-time polymerase chain reaction (PCR) system to quantitate both human patient circulating tumor DNA (ctDNA) and mouse DNA. In preferred embodiments, both PCR amplifications are done simultaneously in a multiplex, and a highly polymorphic human DNA target sequence is amplified for high sensitivity, allowing for small volume samples, typically 50-100 ?L, of mouse blood. Serial evaluations are possible because the mouse can survive withdrawal of these small volumes of blood. A related method allows for quantitation of ctDNA in the presence of human immune cells added to a “humanized” mouse. These relatively quick and easy methods of determining tumor burden in PDX mice can have predictive value for the efficacy of cancer treatments in human patients.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: May 4, 2021
    Inventor: Sudhir Sinha
  • Patent number: 10996212
    Abstract: Methods of forming a chip with fluidic channels include forming (e.g., milling) at least one nanofunnel with a wide end and a narrow end into a planar substrate, the nanofunnel having a length, with width and depth dimensions that both vary over its length and forming (e.g., milling) at least one nanochannel into the planar substrate at an interface adjacent the narrow end of the nanofunnel.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: May 4, 2021
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: John Michael Ramsey, Laurent Menard, Jinsheng Zhou, Michael Rubinstein, Sergey Panyukov